Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;106(9):e3519–e3532. doi: 10.1210/clinem/dgab320

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 3. — Effects of fezolinetant on A, adjusted mean change in E₂ based on ANCOVA; B, endometrial thickness over time; and C, menses frequency, ITT population. ^aP < .05; ^bP < .01. Change in E₂ is based on least squares mean percentage change from the ANCOVA model with treatment group as a fixed factor and baseline value as a covariate. ANCOVA, analysis of covariance; E₂, estradiol; ITT, intent-to-treat.